This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.
Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Professional and Managed services units, and international revenue growth.
DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) first-quarter earnings benefit from solid segmental performance.
Medical Products Stock Earnings on Apr 30: BAX, IDXX & More
by Zacks Equity Research
The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.
Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.
Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Masimo (MASI) sees solid growth in key Product segment in Q1.
Is ResMed (RMD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (RMD) Outperforming Other Medical Stocks This Year?
Ecolab (ECL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Strength in the Global Industrial and Institutional segments drives Ecolab's (ECL) first-quarter results.
Here's Why You Should Retain Inogen (INGN) Stock for Now
by Zacks Equity Research
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
by Zacks Equity Research
Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.
Zacks.com featured highlights include: Keysight Technologies, ResMed, Cigna and Jack Henry & Associates
by Zacks Equity Research
Zacks.com featured highlights include: Keysight Technologies, ResMed, Cigna and Jack Henry & Associates
AMN Healthcare Inks Deal to Address Healthcare System Needs
by Zacks Equity Research
This partnership is expected to boost AMN Healthcare's (AMN) Other Workforce Solutions segment.
Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical Systems (MMSI) has registered an increase in revenues at both its key operating segments in Q1
Add These 4 GARP Stocks to Your Portfolio for Maximum Returns
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
ResMed (RMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) Q3 Earnings to Gain From Growing Ventilator Sales
by Zacks Equity Research
ResMed (RMD) is expected to have gained from increased adoption of flagship products and a ramped-up ventilator production capacity in Q3 amid the coronavirus pandemic.
Here's Why You Should Retain NextGen Healthcare Stock Now
by Zacks Equity Research
NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and robust demand for other NextGen solutions.
Here's Why You Should Add Tandem Diabetes to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.
Here's Why You Should Hold on to HMS Holdings Stock Now
by Zacks Equity Research
HMS Holdings (HMSY) continues to benefit from strong PI solutions and TPM. However, stiff competition remains a concern.
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec
by Zacks Equity Research
Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens (WBA) registers growing demand for Retail Pharmacy & Pharmaceutical Wholesale products in Q2.
Masimo Collaborates With Samsung to Help Fight Coronavirus
by Zacks Equity Research
Masimo (MASI) and Samsung Electronics America collaborate to bring Masimo SafetyNet Patient App on the latter's select smartphones for faster distribution of Masimo SafetyNet to COVID-19 patients.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, margin contraction remains a woe.
Abbott Launches Antibody Test to Detect Coronavirus Infection
by Zacks Equity Research
Abbott (ABT) launches a lab-based serology blood test to detect the presence of antibodies post the coronavirus infection.
Here's Why You Should Retain Accuray in Your Portfolio
by Sriparna Ghosal
Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.